| 51 |
35207759 | Clinical Observation of SGLT2 Inhibitor Therapy for Cardiac Arrhythmia and Related Cardiovascular Disease in Diabetic Patients with Controlled Hypertension. | 2022 Feb 12 |
2 |
| 52 |
35212512 | Diabetes mellitus and heart failure: an update on pathophysiology and therapy. | 2022 Jun |
2 |
| 53 |
35216451 | Old and Novel Therapeutic Approaches in the Management of Hyperglycemia, an Important Risk Factor for Atherosclerosis. | 2022 Feb 20 |
1 |
| 54 |
35234661 | Effects of SGLT2 inhibition on lipid transport in adipose tissue in type 2 diabetes. | 2022 Apr 15 |
1 |
| 55 |
35235172 | Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition. | 2022 Mar |
2 |
| 56 |
35235659 | Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose. | 2022 Jun 2 |
2 |
| 57 |
35237171 | Sodium, Glucose and Dysregulated Glucagon Secretion: The Potential of Sodium Glucose Transporters. | 2022 |
1 |
| 58 |
35251794 | Frequency of Urinary Tract Infections in Type 2 Diabetic Patients Taking Dapagliflozin. | 2022 Jan |
1 |
| 59 |
35252207 | The Intricate Crosstalk Between Insulin and Pancreatic Ductal Adenocarcinoma: A Review From Clinical to Molecular. | 2022 |
1 |
| 60 |
35281930 | Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism. | 2022 |
2 |
| 61 |
35303075 | Association Between SGLT2 Inhibitors vs DPP4 Inhibitors and Renal Outcomes Among Patients With Type 2 Diabetes. | 2022 Jun 16 |
1 |
| 62 |
35322793 | SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function. | 2022 May |
1 |
| 63 |
35344615 | Association between sodium-glucose co-transporter 2 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: a nationwide population-based cohort study. | 2022 Mar 28 |
1 |
| 64 |
35352579 | Relationship of concomitant anti-diabetic drug administration with sodium-glucose co-transporter 2 inhibitor-related ketosis. | 2022 Mar |
1 |
| 65 |
35352682 | Canagliflozin-associated severe hyponatremia: a rare and potentially adverse effect? | 2022 Mar 1 |
1 |
| 66 |
35365032 | The efficacy and safety of dapagliflozin combined with oral hypoglycemic agents in patients with type 2 diabetes: a systematic review and meta-analysis. | 2022 Mar |
2 |
| 67 |
35367765 | Impact of anti-diabetic sodium-glucose cotransporter 2 inhibitors on tumor growth of intractable hematological malignancy in humans. | 2022 May |
3 |
| 68 |
35370232 | Two Cases of Thyrotoxicosis and Euglycemic Diabetic Ketoacidosis Under Sodium-glucose Transport Protein 2 Inhibitor Treatment. | 2022 Apr 2 |
1 |
| 69 |
35389005 | [About the safety profile of SGLT2 inhibitors]. | 2022 Apr |
1 |
| 70 |
35402477 | New Diabetic Medication Sodium-Glucose Cotransporter-2 Inhibitors Can Induce Euglycemic Ketoacidosis and Mimic Surgical Diseases: A Case Report and Review of Literature. | 2022 |
1 |
| 71 |
35409011 | An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors. | 2022 Mar 26 |
3 |
| 72 |
35409028 | SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease. | 2022 Mar 27 |
1 |
| 73 |
35413307 | Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines. | 2022 Apr 9 |
1 |
| 74 |
35414444 | Sodium glucose cotransporter-2 inhibitors protect the cardiorenal axis: Update on recent mechanistic insights related to kidney physiology. | 2022 Jun |
1 |
| 75 |
35421452 | Characteristics and molecular mechanisms through which SGLT2 inhibitors improve metabolic diseases: A mechanism review. | 2022 Jul 1 |
2 |
| 76 |
35434529 | Canagliflozin and Dapagliflozin Attenuate Glucolipotoxicity-Induced Oxidative Stress and Apoptosis in Cardiomyocytes via Inhibition of Sodium-Glucose Cotransporter-1. | 2022 Apr 8 |
3 |
| 77 |
35439410 | Targeting Glucose Transport Proteins for Diabetes Management: Regulatory Roles of Food-Derived Compounds. | 2022 May 4 |
1 |
| 78 |
35447305 | Sodium-glucose cotransporter type 2 inhibitors and cardiac arrhythmias. | 2022 Apr 18 |
4 |
| 79 |
35508700 | Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations. | 2022 Jul |
1 |
| 80 |
35510595 | Sodium-glucose co-transporter-2 inhibitors in heart failure with reduced ejection fraction: Current evidence and future perspectives. | 2022 Jul |
2 |
| 81 |
35563495 | Effects of Sodium-Glucose Co-Transporter-2 Inhibitors on Pancreatic β-Cell Mass and Function. | 2022 May 4 |
1 |
| 82 |
35573514 | An Unsuspected Case of Euglycemic Diabetic Ketoacidosis With Twists. | 2022 Apr |
1 |
| 83 |
35586391 | Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Treatment in Type 1 Diabetes in a Tertiary Care Center in Saudi Arabia. | 2022 Jan |
1 |
| 84 |
35589418 | Etiopathogenesis of kidney disease in minority populations and an updated special focus on treatment in diabetes and hypertension. | 2022 Jun |
1 |
| 85 |
35602255 | ANMCO statement on the use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a practical guide for a streamlined implementation. | 2022 May |
2 |
| 86 |
35614469 | The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. | 2022 May 25 |
4 |
| 87 |
35628485 | Empagliflozin Treatment Attenuates Hepatic Steatosis by Promoting White Adipose Expansion in Obese TallyHo Mice. | 2022 May 18 |
2 |
| 88 |
31741057 | Assessing the health-related quality of life in type 2 diabetes patients treated with insulin and oral antidiabetic agents. | 2021 Mar |
1 |
| 89 |
31882264 | Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology. | 2021 Jan |
2 |
| 90 |
32006266 | Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors. | 2021 |
3 |
| 91 |
32490567 | Letter to the Editor: Sodium-Glucose Cotransporter-2 Inhibitors Are Not the Magic Pills for Control of Ascites in Cirrhosis and Diabetes. | 2021 Feb |
1 |
| 92 |
32530554 | Sodium-glucose cotransporter 2 inhibitors compared with other glucose-lowering drugs in Japan: Subanalyses of the CVD-REAL 2 Study. | 2021 Jan |
1 |
| 93 |
32536199 | Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease. | 2021 Feb |
1 |
| 94 |
32593203 | Sodium-glucose cotransporter 2 inhibitors reduce day-to-day glucose variability in patients with type 1 diabetes. | 2021 Feb |
3 |
| 95 |
32597517 | Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real-world clinical practice: Results of a 36-month post-marketing surveillance study (J-STEP/LT). | 2021 Feb |
3 |
| 96 |
32721227 | Retrospective Analysis of the Renoprotective Effects of Long-Term Use of Six Types of Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. | 2021 Feb |
1 |
| 97 |
32767909 | Use of Sodium-Glucose Co-Transporter-2-Inhibitors (SGLT2-Is) and Risk of Lower Limb Amputation. | 2021 |
2 |
| 98 |
33005037 | Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation. | 2021 Jan |
1 |
| 99 |
33034138 | High urinary glucose is associated with improved renal prognosis in patients with diabetes mellitus. | 2021 Jun |
1 |
| 100 |
33043620 | Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes. | 2021 Feb |
1 |